• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Colorectal Cancer Reports >Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
【24h】

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

机译：抗EGFR疗法诱导的转移性大肠癌毒性反应的管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Use of anti-epidermal growth factor receptor (anti-EGFR) agents has yielded significant advances in the treatment of patients with metastatic colorectal cancer. In fact these drugs, which include the monoclonal antibodies cetuximab and panitumumab, can be delivered both as a single agent and in combination with chemotherapy, achieving better survival and quality of life and in some cases also resectability of metastases. However, these agents can result in the development of toxicities that are usually different from those observed with chemotherapy alone. For the management of these adverse effects, proper knowledge is mandatory. Skin toxicity is the most frequent adverse effect. Other toxicities can be observed, such as hypomagnesemia, gastrointestinal toxicity, and thromboembolic events. Severe infusion reactions can be life-threatening. For these reasons a review of anti-EGFR-drug-related toxicity is useful for clinical practice.
机译：抗表皮生长因子受体（anti-EGFR）药物的使用已在转移性结直肠癌患者的治疗方面取得了重大进展。实际上，这些药物（包括西妥昔单抗和帕尼单抗的单克隆抗体）既可以作为单一药物给药，也可以与化学疗法联合给药，从而获得更好的生存率和生活质量，在某些情况下还具有转移的可切除性。但是，这些药物可能导致产生的毒性通常不同于仅通过化学疗法观察到的毒性。为了控制这些不利影响，必须具备适当的知识。皮肤毒性是最常见的不良反应。可以观察到其他毒性，例如低镁血症，胃肠道毒性和血栓栓塞事件。严重的输注反应可能会危及生命。由于这些原因，抗EGFR药物相关毒性的综述对于临床实践是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号